Delving into the Latest Updates on Alfresa Pharma Corp. with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Infectious Diseases

Small molecule drug

Synthetic peptide

Contrast agent

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	29
Infectious Diseases	22
Endocrinology and Metabolic Disease	15
Immune System Diseases	14
Hemic and Lymphatic Diseases	6
Neoplasms	5

Top 5 Drug Type	Count

Small molecule drug	73
Synthetic peptide	1
Contrast agent	1

Top 5 Target	Count

GABAA receptor(Gamma-aminobutyric acid A receptor)	7
D2 receptor(Dopamine D2 receptor)	4
cGMP-PDE(3',5'-cyclic phosphodiesterase)	2
PBPs(Bacterial penicillin-binding protein)	2
Sodium channels	2

Author: Ohtake, Kazuko ; Totani, Masayuki ; Tanimoto, Kazuhito ; Ihara, Hiroshi ; Itoh, Susumu ; Adachi, Hiroshi ; Fujimura, Yoshiyuki ; Osawa, Susumu ; Takada, Daiichiro ; Ida, Takehisa ; Watahiki, Kensuke ; Shinzaki, Akihiro ; Hirano, Yuuki ; Kinpara, Kiyoko ; Kiuchi, Sachiko ; Nejime, Tetsuya ; Ueda, Shigeru ; Ishibashi, Midori ; Miura, Yoshinori

Background In vitro diagnostic bilirubin reagents based on oxidation with bilirubin oxidase or vanadic acid for total and direct-reacting bilirubin are widely used in Japan; however, their reactivity to unconjugated and conjugated bilirubin and delta bilirubin has not been completely disclosed by manufacturers. We used artificially prepared bilirubin materials to investigate the reactivity with four in vitro diagnostic bilirubin reagents. Methods Porcine unconjugated bilirubin solution, chemically synthesized ditaurobilirubin solution, and chemically synthesized delta bilirubin solution were used as surrogates of naturally occurring unconjugated bilirubin, conjugated bilirubin, and delta bilirubin, respectively. The total bilirubin and direct-reacting bilirubin concentrations were measured by three bilirubin oxidase methods and one vanadic acid method, and the observed concentrations were compared with those obtained by the diazo-based reference measurement procedure. Results The unconjugated bilirubin and delta bilirubin concentrations were similar when any of the four in vitro diagnostic bilirubin reagents were used during total bilirubin measurement. This was consistent with reference measurement procedure and exhibited a converged inter-method variation. Compared with reference measurement procedure, significantly low ditaurobilirubin concentrations were observed by the in vitro diagnostic bilirubin reagents despite the converged inter-method variation. In delta bilirubin measurement, some reagents reacted doubtfully with unconjugated bilirubin, while showed lower ditaurobilirubin concentrations than its corresponding total bilirubin concentration. Reactivity with delta bilirubin was different for each method including reference measurement procedure. Some reagents were developed to react less with delta bilirubin and others to strongly react with delta bilirubin. Conclusions We revealed the reactivity of IVD-TB and IVD-DB reagents to artificially prepared bilirubin materials, and their consistency with reference measurement procedure. The delta bilirubin data results vary depending on the reagents used.

01 Apr 2021·Sleep MedicineQ3 · MEDICINE

Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time: a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study

Q3 · MEDICINE

Article

Author: Tabata, Toshiyuki ; Tsukimori, Naoji ; Inoue, Yuichi

BACKGROUNDFew treatments are available for patients with idiopathic hypersomnia (IH). Modafinil, an established treatment for narcolepsy, was tested for efficacy and safety in Japanese patients with IH without long sleep time.METHODSThis multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study was conducted at 20 institutions in Japan. Patients who met the diagnostic criteria of IH in the International Classification of Sleep Disorders (second edition) were included. The study comprised a ≥17-day observation period and a 3-week treatment period during which modafinil (200 mg) or placebo was administered orally once daily (in the morning). The primary efficacy endpoint was change in mean sleep latency on the Maintenance of Wakefulness Test (MWT). Adverse events (AEs) were also recorded to evaluate safety.RESULTSIn total, 123 patients were screened and 71 were randomized to receive modafinil (N = 34) or placebo (N = 37). Patients treated with modafinil experienced a significantly prolonged mean sleep latency on the MWT at the end of the study compared with placebo (5.02 min, 95% confidence interval: 3.26-6.77 min; p < 0.001). AEs occurred in 58.8% (20/34) and 27.0% (10/37) of patients in the modafinil and placebo groups, respectively. Frequent AEs in the modafinil group were headache (n = 6), dry mouth (n = 3), and nausea (n = 3); no clinically significant AEs occurred.CONCLUSIONModafinil was shown to be an effective and safe treatment for excessive daytime sleepiness in patients with IH without long sleep time.CLINICAL TRIAL REGISTRATIONJapicCTI; 142539.

01 Jan 2019·Journal of the Neurological SciencesQ4 · MEDICINE

Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus

Q4 · MEDICINE

Article

Author: Tabata, Toshiyuki ; Hamano, Shin-Ichiro ; Miki, Masuo ; Sugai, Kenji ; Fukuyama, Takako ; Osawa, Makiko

BACKGROUNDNo dosing regimen has been established for the initial treatment of pediatric status epilepticus with intravenous midazolam. We therefore evaluated the efficacy, safety, and pharmacokinetics of bolus and continuous midazolam infusion.METHODSThis open-label, prospective, multicenter study involved 34 Japanese children with status epilepticus unresponsive to diazepam. An initial bolus of 0.15 mg/kg midazolam was given, with additional doses of 0.1-0.3 mg/kg up to a cumulative dose of 0.6 mg/kg. A continuous infusion was initiated at 0.1 mg/kg/h (maximum 0.4 mg/kg/h) for patients at high risk of recurrence or in whom seizure reduction was achieved, and continued for 24 h after seizure cessation. Seizure cessation was assessed based on clinical observation (disappearance of motor symptoms regardless of recovery of consciousness), rather than the disappearance of electroencephalography abnormalities.RESULTSThe seizure cessation rate with bolus midazolam was 88%. The cumulative dose was ≤0.3 mg/kg in 90% of patients who responded to bolus administration. Adverse events were observed in three patients; one had mild respiratory depression that required supplemental oxygen and bag-valve-mask ventilation. Elimination half-life was 0.999 ± 0.241 h in seven patients. Total body clearance ranged from 423 to 1220 mL/h/kg in older children but was notably higher in a 10-month-old infant (2010 mL/h/kg).CONCLUSIONSThe efficacy and safety of midazolam were demonstrated in children with status epilepticus, suggesting that intravenous midazolam is suitable as first-line treatment.

1

News (Medical) associated with Alfresa Pharma Corp.

29 Dec 2004

·www.biospace.com

Alfresa Pharma Releases Automated Immunochemical Analyzer And Reagent For Fecal Occult Blood Tests

Tokyo (JCNN) - Alfresa Holdings (TSE: 2784) has announced that its subsidiary Alfresa Pharma has launched the Hemotect NS-Plus C, an automated immunochemical analyzer, and its proprietary reagent Nescoat HemoPlus for fecal occult blood tests.

100 Deals associated with Alfresa Pharma Corp.

Login to view more data

100 Translational Medicine associated with Alfresa Pharma Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

74

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Modafinil ( DAT )	Sleep Apnea, Obstructive More	Approved
Sodium Fusidate	Secondary infection More	Approved
Ofloxacin ( Bacterial DNA gyrase x Bacterial top IV )	Otitis Media More	Approved
Irinotecan Hydrochloride ( TOP1 )	Small Cell Lung Cancer More	Approved
Norepinephrine Bitartrate ( α1A-AR x α1B-AR )	Hypotension More	Approved